Literature DB >> 26014205

Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type.

Woo Jin Lee1, Kwang Hee Won, Chong Hyun Won, Sung Eun Chang, Jee Ho Choi, Kee Chan Moon, Chan-Sik Park, Jooryung Huh, Cheolwon Suh, Mi Woo Lee.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) can be separated into 2 groups: nodal and extranodal disease. The aim of this study was to analyse the clinical features of skin lesions and survival outcomes of cutaneous DLBCL according to the primary tumour site. A total of 44 patients with cutaneous DLBCL were classified as primary cutaneous DLBCL, leg type or cutaneous DLBCL secondary to primary disease. Although skin lesion characteristics did not differ significantly between groups, extensive cutaneous lesions were more often observed in secondary cutaneous DLBCL compared with DLBCL, leg type. Secondary cutaneous DLBCL was more commonly associated with an advanced stage and higher International Prognostic Index score than DLBCL, leg type. DLBCL, leg type demonstrated a better survival outcome than secondary cutaneous DLBCL. The multiplicity of skin lesions and time-point of cutaneous involvement were associated with prognosis in secondary cutaneous DLBCL. Survival outcomes and prognostic factors differ depending on the primary tumour site of cutaneous DLBCL.

Entities:  

Mesh:

Year:  2016        PMID: 26014205     DOI: 10.2340/00015555-2139

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

1.  Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.

Authors:  Xiaolong Alan Zhou; Abner Louissaint; Alexander Wenzel; Jingyi Yang; Maria Estela Martinez-Escala; Andrea P Moy; Elizabeth A Morgan; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; Amir Behdad; Lorenzo Cerroni; David M Weinstock; Jaehyuk Choi
Journal:  J Invest Dermatol       Date:  2018-05-30       Impact factor: 8.551

2.  Cutaneous Presentation of Diffuse Large B-Cell Lymphoma.

Authors:  Robin George Manappallil; Abhay Mani Martin; Neena Mampilly; Kunivayalil Sajeevan
Journal:  Eurasian J Med       Date:  2017-06

3.  Figurate erythema for 20 years.

Authors:  Christine P Lin; Patrick M Mulvaney; Christine G Lian; Fei-Shiuann Clarissa Yang
Journal:  JAAD Case Rep       Date:  2019-05-21

4.  Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.

Authors:  Dan Yang; Wei-Ping Zhang; Jian-Min Yang; Miao-Xia He; Chao Cheng; Jie Chen
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

5.  A Unique Presentation of Cutaneous Diffuse Large B-Cell Lymphoma.

Authors:  Mary Awad; Erik Holzwanger; Sandeep Jubbal
Journal:  Case Rep Dermatol Med       Date:  2020-04-07

6.  Diffuse Large B Cell Lymphoma with Cutaneous and Gastrointestinal Involvement.

Authors:  Aye-Mya-Mya Kyaw; Than-Than Aye; Lin-Lin Htun
Journal:  Case Rep Gastrointest Med       Date:  2022-02-27

7.  lncRNA GAS5, as a ceRNA, inhibits the proliferation of diffuse large B‑cell lymphoma cells by regulating the miR‑18a‑5p/RUNX1 axis.

Authors:  Yinsha Miao; Xiaodong Chen; Mengting Qin; Wen Zhou; Yang Wang; Yanhong Ji
Journal:  Int J Oncol       Date:  2021-10-26       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.